Stock Taper 
CRDF
$0.94
▼ DOWN 4.67% (-0.05)
KEY STATISTICS
Market Cap$72.45 M
52w High$3.31
52w Low$0.76
Dividend Yield—
Frequency—
P/E-1.57
Volume526.30K
Shares Out.77.07M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Mani Mohindru
COMPENSATION 2026
Salary$0
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$0
Total$2,266,106
ABOUT
SECTOR
Healthcare
WENT PUBLIC
July 27, 2004
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
31
PRICE TARGET
Target High$2.00
Target Low$2.00
Target Median$2.00
Target Consensus$2.00
UPCOMING EARNINGS
DateNov 5, 2026
DayThursday
Rev. Est.$75.63K
NOV
5
THU
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 2019-02-20 | Reverse | 1:6 |
| 2018-06-04 | Reverse | 1:12 |
| 2012-05-30 | Reverse | 1:6 |
| 2004-07-27 | Forward | 111:1 |
PRICE
$0.94 ▼ DOWN 4.67% (−$0.05)About Cardiff Oncology, Inc.
https://www.cardiffoncology.com ↗Cardiff Oncology, Inc. is a San Diego-based clinical-stage biotech developing cancer treatments like onvansertib and various PLK inhibitors, primarily serving pharmaceutical partners across solid tumors, leukemias, and prostate cancer.
INDUSTRY
Biotechnology
A PRODUCT CARDIFF ONCOLOGY, INC. IS KNOWN FOR
Onvansertib
Onvansertib is a highly selective oral PLK1 inhibitor developed by Cardiff Oncology, currently in clinical trials as a leading cancer therapy, especially for RAS-mutated metastatic colorectal cancer.
Revenue by Products
| Icon | PRODUCT | Q2-2019 | Q3-2019 | Q4-2019 |
|---|---|---|---|---|
 | Service | $101.43K | — | — |
 | Royalty | $36.85K | $51.69K ▲ | $92.58K ▲ |
ETFS HOLDING THIS STOCK
ETFS HOLDING
12
LISTED HERE
2
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
32.37%
HOLDERS
148
TOP 12 OF 148 · RANKED BY POSITION SIZE
Blackrock, Inc.
Vanguard Group Inc
Laurion Capital Management LP
Blackrock Inc.
Pfizer Inc
Blair William & Co/Il
Acorn Capital Advisors, LLC
Geode Capital Management, LLC
Franklin Resources Inc
State Street Corp
Two Sigma Investments, LP
Flputnam Investment Management Co
RATINGS SNAPSHOT
Overall rating: C
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2
INSIDER TRADES
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Mohindru Mani
Purchase · 34.4K shares
2026-07-14
★
DIRECTOR
PACE GARY W
Purchase · 687.3K shares
2026-07-14
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Mohindru Mani
Purchase · 34.4K shares
2026-07-14
★
DIRECTOR
PACE GARY W
Purchase · 687.3K shares
2026-07-14
MOST RECENT ANALYST GRADES
GRADE SUMMARY
HOLD 2
MARKET PERFORM 1
NEUTRAL 1
OVERWEIGHT 1
5 GRADES IN THE LAST 12 MONTHS
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 FBRX | $76.99 | COMPARE |
 PEPG | $3.08 | COMPARE |
 IPHA | $2.22 | COMPARE |
 CRBP | $10.91 | COMPARE |
 MOLN | $4.50 | COMPARE |
 MIST | $1.16 | COMPARE |
 RANI | $0.84 | COMPARE |
 ELTX | $2.84 | COMPARE |